You are here:
Di (2-ethylhexyl)phthalate (DEHP)
- IRIS Summary (PDF) (14 pp, 121 K)
- Status: Di (2-ethylhexyl)phthalate (DEHP) is not being reassessed by IRIS at this time.
Health Hazard Assessments for Effects Other than Cancer
Reference Dose for Oral Exposure (RfD) (PDF) (14 pp, 121 K)
last updated: 01/31/1987
Reference Concentration for Inhalation Exposure (RfC) (PDF) (14 pp, 121 K)
Not assessed under the IRIS Program.
Weight of Evidence for Cancer (PDF) (14 pp, 121 K)
last updated: 09/07/1988
|WOE Characterization||Framework for WOE Characterization|
|B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)||Guidelines for Carcinogen Risk Assessment (US EPA, 1986)|
- Orally administered DEHP produced significant dose-related increases in liver tumor responses in rats and mice of both sexes.
- This may be a synopsis of the full weight-of-evidence narrative.
Oral Slope Factor:
1.4 x10 -2 per mg/kg-day
Drinking Water Unit Risk: 4 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular carcinoma and adenoma (NTP, 1982)
Not Assessed under the IRIS Program.
You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.